Vimarsana
Biggest News Aggregation in the World

Partial Remission News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Partial Remission. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Partial Remission Today - Breaking & Trending Today

Gloria Biosciences Announces Zimberelimab Approved in China for the Treatment of Recurrent or Metastatic Cervical Cancer - Vimarsana News

Gloria Biosciences Announces Zimberelimab Approved in China for the Treatment of Recurrent or Metastatic Cervical Cancer

/PRNewswire/ -- Guangzhou Gloria Biosciences ("GloriaBio"), a commercial stage biopharmaceutical company focusing on the discovery, development and...

Nigeria-Born Professor, Benjamin Nwosu Bags American Diabetes Association Award Over Life-Saving Research - Vimarsana News

Nigeria-Born Professor, Benjamin Nwosu Bags American Diabetes Association Award Over Life-Saving Research

A Nigeria-born Professor of Pediatrics at the Zucker School of Medicine at Hofstra/Northwell, Dr Benjamin Udoka Nwosu has bagged the American Diabetes Association Research Award. It was learnt that the American Diabetes Association in May held its Research Dinner at the Garden City Hotel in New York, and bestowed prestigious research awards on three researchers in the field of diabetology. One of the awardees was Nigeria's Dr. Benjamin Udoka Nwosu, the Chief of Endocrinology at the Cohen Children's Medical Center of New York.

AbbVie Showcases the Depth of its Rheumatology Portfolio with New Data Presented at the EULAR 2021 Virtual Congress of Rheumatology - Vimarsana News

AbbVie Showcases the Depth of its Rheumatology Portfolio with New Data Presented at the EULAR 2021 Virtual Congress of Rheumatology

AbbVie Showcases the Depth of its Rheumatology Portfolio with New Data Presented at the EULAR 2021 Virtual Congress of Rheumatology ABBVie today announced that it will present new data from a total of 41 abstracts covering its portfolio of immunology assets, including RINVOQ ® SKYRIZI ® HUMIRA ® and its pipeline across multiple rheumatic diseases at the EULAR 2021 Virtual Congress of Rheumatology, to be held virtually June 2-5 . Among the data presented will be new three-year and one-year efficacy and safety data for RINVOQ for the treatment … – ABBVie (NYSE: ABBV) today announced tha...